Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hogan

Showing results (991-1000 of 1,303) with videos related to

Pageof 131
Sort By:
American Journal of Hematology|October 1, 2011
Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myelomaGuner Hayri Ozsan, Ivana N Micallef, Angela Dispenzieri, et al.
Kidney International|January 23, 2019
Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceJürgen Floege, Sean J Barbour, Daniel C Cattran, et al.
Mayo Clinic Proceedings|August 6, 2019
Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013Aref Al-Kali, Darci Zblewski, James M Foran, et al.
Bone Marrow Transplantation|March 9, 2010
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignanciesS G Holtan, W J Hogan, M A Elliott, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2026
Generation and MHC class II loading of an endogenous influenza epitope revealed by a T cell receptor-like antibodyLinlin Yang, Michael J Hogan, Stephen D Carro, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|September 20, 2016
Vancomycin-resistant Enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemiaMehrdad Hefazi, Moussab Damlaj, Hassan B Alkhateeb, et al.
Nature Immunology|October 12, 2023
Cryptic MHC-E epitope from influenza elicits a potent cytolytic T cell responseMichael J Hogan, Nikita Maheshwari, Bridget E Begg, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 1, 2015
Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center ExperienceMoussab Damlaj, Nanna H Sulai, Jennifer L Oliveira, et al.
Transplantation|September 14, 2006
Partial donor-specific tolerance to delayed skin grafts after rejection of hematopoietic cell graftMurad Y Yunusov, Christian S Kuhr, George E Georges, et al.
BMC Medical Genetics|October 1, 2018
Detecting clinically actionable variants in the 3' exons of PMS2 via a reflex workflow based on equivalent hybrid capture of the gene and its pseudogeneGenevieve M Gould, Peter V Grauman, Mark R Theilmann, et al.
Pageof 131

Showing results (991-1000 of 1,303) with videos related to

Sort By:
Pageof 131
American Journal of Hematology|October 1, 2011
Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myelomaGuner Hayri Ozsan, Ivana N Micallef, Angela Dispenzieri, et al.
Kidney International|January 23, 2019
Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceJürgen Floege, Sean J Barbour, Daniel C Cattran, et al.
Mayo Clinic Proceedings|August 6, 2019
Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013Aref Al-Kali, Darci Zblewski, James M Foran, et al.
Bone Marrow Transplantation|March 9, 2010
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignanciesS G Holtan, W J Hogan, M A Elliott, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2026
Generation and MHC class II loading of an endogenous influenza epitope revealed by a T cell receptor-like antibodyLinlin Yang, Michael J Hogan, Stephen D Carro, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|September 20, 2016
Vancomycin-resistant Enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemiaMehrdad Hefazi, Moussab Damlaj, Hassan B Alkhateeb, et al.
Nature Immunology|October 12, 2023
Cryptic MHC-E epitope from influenza elicits a potent cytolytic T cell responseMichael J Hogan, Nikita Maheshwari, Bridget E Begg, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 1, 2015
Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center ExperienceMoussab Damlaj, Nanna H Sulai, Jennifer L Oliveira, et al.
Transplantation|September 14, 2006
Partial donor-specific tolerance to delayed skin grafts after rejection of hematopoietic cell graftMurad Y Yunusov, Christian S Kuhr, George E Georges, et al.
BMC Medical Genetics|October 1, 2018
Detecting clinically actionable variants in the 3' exons of PMS2 via a reflex workflow based on equivalent hybrid capture of the gene and its pseudogeneGenevieve M Gould, Peter V Grauman, Mark R Theilmann, et al.
Pageof 131